

VEDOLIZUMAB (ENTYVIO®) PRESCRIBER ORDER FORM		
FAX COMPLETED FORM, INSURANCE INFORMATION, CLINICAL DOCUMENTATION (LATEST NOTES & LABS) to (757) 466-1128		
<input type="checkbox"/> NEW PATIENT OR <input type="checkbox"/> CHANGE ORDER: Drug Change Dose Change Interval Change		
Patient Name:	Phone:	Date of Birth:
Address:		
Allergies:		
Height:	<input type="checkbox"/> inches <input type="checkbox"/> cm	Weight: <input type="checkbox"/> lbs <input type="checkbox"/> kg
CLINICAL INFORMATION		
Primary Diagnosis Description:		ICD-10 Code:
Is this the first dose? <input type="checkbox"/> Yes <input type="checkbox"/> No – date of next dose due: _____		
Treatments Tried and Failed:		
VEDOLIZUMAB (ENTYVIO®) PRESCRIPTION		
Vedolizumab (ENTYVIO®) refill as directed x 1 year		
IV Regimen	<input type="checkbox"/> Initial Dose; Infuse 300mg IV over at least 30 minutes on Weeks 0, 2, and 6. <input type="checkbox"/> Maintenance Dose; Infuse 300mg IV over at least 30 minutes every 8 weeks. <input type="checkbox"/> Other: _____	
ANCILLARY ORDERS		
Pre-Medication Orders:		
<input type="checkbox"/> Acetaminophen 650mg PO 30 minutes before infusion. <input type="checkbox"/> Diphenhydramine 25mg PO 30 minutes before infusion. <input type="checkbox"/> Methylprednisolone Succinate 125mg IV push 20 minutes before infusion. <input type="checkbox"/> Other: _____		
PRN Hypersensitivity Meds:		
<ul style="list-style-type: none"> • Epinephrine 0.3mg • Solu-Cortef 100mg • Solu-Medrol 125mg • Diphenhydramine 25-50mg • NS 500 ML (>30kg) 		
<i>I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.</i>		
Prescriber Signature:		Date:
PRESCRIBER INFORMATION		
Prescriber Name:	Phone:	Fax:
Address:	NPI:	
City, State:	Zip:	Office Contact:
<small>CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to who it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of the information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.</small>		